ALEXANDRIA, Va., Oct. 19 -- Abbott Laboratories, Abbott Park, Illinois, and Icahn School of Medicine at Mount Sinai, New York, have been assigned a patent (No. 10,444,242, initially filed June 22, 2016) developed by nine co-inventors for "detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies." The co-inventors are Robert Ziemann, Abbott Park, Illinois, April Ahlberg, Abbott Park, Illinois, David Hawksworth, Abbott Park, Illinois, Bryan Tieman, Abbott Park, Illin . . .